Gilead (GILD) Lags Other Biotechs Following HCV Data From Regulus (RGLS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
FBR Capital Reiterates Outperform Following Regulus Therapeutics' (RGLS) Positive RG-101 Results
February 17, 2016 2:09 PM ESTFBR Capital reiterated an Outperform rating and $30.00 price target on Regulus Therapeutics (NASDAQ: RGLS) following the company's announcement of positive results from its interim analysis of RG-101 in combination with direct-acting antivirals. In patients evaluated for eight-week follow-up, 97% (37/38) of the patients demonstrated HCV RNA viral load measurements below the limit of quantification. FBR expects additional data at the European Association for the Study of the Liver (EASL) meeting... More
Regulus Therapeutics (RGLS) PT Lifted to $48 at Wedbush
February 17, 2016 11:46 AM ESTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Regulus Therapeutics (NASDAQ: RGLS) to $48.00 (from $42.00) after interim results suggest with only 29 days treatment RG-101 / DAA treatment combinations were able to reduce HCV viral load to BLOQ in 97% of patients at 8 week follow.
Moussatos commented, "Regulus announced positive interim... More
Needham & Company Reiterates Bullish View on Regulus Therapeutics (RGLS) Following Latest Data
February 17, 2016 11:38 AM ESTNeedham & Company analyst Alan Carr reiterated a Buy rating and $25 price target on Regulus Therapeutics (NASDAQ: RGLS) following positive Phase 2 RG-101 results.
Pts were administered an injection of RG-101, a 4-wk regimen of Harvoni, Olysio, or Daklinza, and then one more injection... More
Regulus Therapeutics (RGLS) Issues Encouraging Update from RG-101 Phase 2 in HCV; Plans Accelerated Development
February 17, 2016 7:33 AM ESTRegulus Therapeutics Inc. (Nasdaq: RGLS) announced interim results from one of the company's ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV). The study was designed to evaluate a shortened, four-week treatment regimen containing a subcutaneous administration of 2 mg/kg of RG-101 at Day 1 and Day 29, in combination with 4 weeks of once/daily approved anti-viral agents Harvoni®, Olysio®, or... More
